Rigel Pharmaceuticals (RIGL) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.56% |
| Dec 31, 2025 | 63.00% |
| Sep 30, 2025 | 18.21% |
| Jun 30, 2025 | 5.33% |
| Mar 31, 2025 | -25.05% |
| Dec 31, 2024 | -42.83% |
| Sep 30, 2024 | -17.21% |
| Jun 30, 2024 | -18.96% |
| Mar 31, 2024 | -18.46% |
| Dec 31, 2023 | -17.72% |
| Sep 30, 2023 | -18.20% |
| Jun 30, 2023 | -17.37% |
| Mar 31, 2023 | -18.17% |
| Dec 31, 2022 | -16.38% |
| Sep 30, 2022 | -18.67% |
| Jun 30, 2022 | -15.47% |
| Mar 31, 2022 | -39.53% |
| Dec 31, 2021 | -11.21% |
| Sep 30, 2021 | -5.51% |
| Jun 30, 2021 | -1.57% |
| Mar 31, 2021 | 0.74% |
| Dec 31, 2020 | -17.93% |
| Sep 30, 2020 | -11.97% |
| Jun 30, 2020 | -8.97% |
| Mar 31, 2020 | -6.89% |
| Dec 31, 2019 | -15.94% |
| Sep 30, 2019 | -14.04% |
| Jun 30, 2019 | -13.93% |
| Mar 31, 2019 | -12.73% |
| Dec 31, 2018 | -12.00% |
| Sep 30, 2018 | -14.27% |
| Jun 30, 2018 | -12.80% |
| Mar 31, 2018 | -21.36% |
| Dec 31, 2017 | -19.03% |
| Sep 30, 2017 | -20.31% |
| Jun 30, 2017 | -18.68% |
| Mar 31, 2017 | -17.24% |
| Dec 31, 2016 | -25.27% |
| Sep 30, 2016 | -23.88% |
| Jun 30, 2016 | -23.02% |
| Dec 31, 2015 | -11.27% |